Key Points
- CEO Johan Spoor bought 47,000 shares at $0.81 each for $38,070, increasing his direct ownership by 79.15% to 106,383 shares.
- Perspective Therapeutics missed quarterly expectations, reporting a loss of $0.27 per share versus the $0.24 consensus and revenue of $0.02 million against estimates of $0.06 million.
- Analysts’ price targets have been cut, though the stock retains a “Moderate Buy” consensus and a $10.10 average target; shares were recently at $0.84.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) CEO Johan Spoor bought 47,000 shares of Perspective Therapeutics stock in a transaction on Wednesday, November 11th. The stock was acquired at an average price of $0.81 per share, with a total value of $38,070.00. Following the completion of the purchase, the chief executive officer directly owned 106,383 shares of the company's stock, valued at approximately $86,170.23. The trade was a 79.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Perspective Therapeutics Stock Up 2.1%
CATX stock opened at $0.84 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 6.61. Perspective Therapeutics, Inc. has a 12 month low of $0.78 and a 12 month high of $6.16. The firm has a 50 day moving average of $2.15 and a two-hundred day moving average of $3.45.
Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. On average, sell-side analysts predict that Perspective Therapeutics, Inc. will post -1.01 earnings per share for the current year.
Institutional Trading of Perspective Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. Provenance Wealth Advisors LLC bought a new stake in Perspective Therapeutics during the 3rd quarter valued at approximately $44,000. Auctus Advisors LLC increased its position in Perspective Therapeutics by 83.6% in the 3rd quarter. Auctus Advisors LLC now owns 37,359 shares of the company's stock worth $103,000 after buying an additional 17,015 shares during the period. Russell Investments Group Ltd. increased its position in Perspective Therapeutics by 53.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company's stock worth $168,000 after buying an additional 21,150 shares during the period. Taylor & Morgan Wealth Management LLC increased its position in Perspective Therapeutics by 127.6% in the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company's stock worth $225,000 after buying an additional 37,000 shares during the period. Finally, Quantinno Capital Management LP bought a new position in Perspective Therapeutics in the 1st quarter worth approximately $273,000. Institutional investors own 54.66% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on CATX shares. Piper Sandler decreased their price objective on shares of Perspective Therapeutics from $16.00 to $14.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. Royal Bank Of Canada downgraded shares of Perspective Therapeutics from an "outperform" rating to a "sector perform" rating and lowered their target price for the stock from $14.00 to $4.00 in a research report on Monday, October 26th. Wedbush restated an "outperform" rating and set a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a report on Tuesday. Bank of America reduced their price target on Perspective Therapeutics from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Friday, August 14th. Finally, BTIG Research reiterated a "buy" rating on shares of Perspective Therapeutics in a research note on Monday, October 26th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, Perspective Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $10.10.
Check Out Our Latest Analysis on CATX
Perspective Therapeutics Company Profile
(
Get Free Report)
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company's investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
